期刊文献+

高分子聚合物逆转/减轻血浆诱导的肺表面活性物质失活的机制

Mechanism of Polymers Reversing/Reducing Inactivation of Surfactant Induced by Plasma
原文传递
导出
摘要 目的探讨高分子聚合物是否能逆转或减轻血浆诱导的肺表面活性物质(PS)失活。方法应用闭泡式表面张力仪分别测定高分子聚合物葡聚糖(Dextran)、聚乙二醇(PEG)和透明质酸(HA)、PS及加入了1%~3%血浆的混合物的最大表面张力(γmax)和最小表面张力(γmin),并计算其稳定系数(S.I.)。结果不同的高分子聚合物、血浆及其混合物的γmin均大于10 mN-m,S.I.小于0.8。PS(0.84 g·L-1)的γmin及S.I.分别是(1.78±0.03)mN-m和1.71±0.01。当PS与1%、2%、3%血浆混合后,其混合物的γmin分别上升为(21.96±0.15)mN-m,(22.31±0.34)mN-m和(28.02±1.36)mN-m;S.I.下降为0.14±0.03,0.12±0.01和0·36±0·03;再加入5%PEG,5%Dextran或0.25%HA后,其γmin分别下降为(1.60±0.04)mN-m,(1.35±0.06)mN-m,(18.66±0·73)mN-m;(1.13±0.01)mN-m,(1.28±0.01)mN-m,(16.68±0.31)mN-m和(1.16±0.01)mN-m,(1.22±0.01)mN-m,(1.23±0·01)mN-m。S.I.分别为1.76±0.01,1.77±0.01,0.31±0.03;1.82±0.01,1.80±0.00,0.46±0.03和1.82±0.01,1.81±0.00,1.81±0.01。PEG(0%、2.5%、5.0%、10.0%)+PS+血浆(2%)组γmin分别为(22.32±0.34)mN-m,(1.09±0.01)mN-m,(1.35±0.06)mN-m,(0.96±0.02)mN-m;Dextran(0%、2.5%、5.0%、10.0%)+PS+血浆组γmin分别为(22.32±0.34)mN-m,(2.03±0·04)mN-m,(1.28±0.01)mN-m,(1.10±0.09)mN-m;HA(0%、0.125%、0.250%、0.500%)+PS+血浆组γmin分别为(22.32±0·34)mN-m,(9.60±0.20)mN-m,(1.22±0.01)mN-m,(0.92±0.01)mN-m。结论在体外实验中,国产PS具有很好的表面活性;高分子聚合物(PEG、Dextran、HA)可以逆转血浆引起的PS失活;与PEG和Dextran比较,HA和PS混合,对抗血浆引起的PS失活效果更好。 Objective To verify whether plasma-induced pulmonary surfactant(PS) inactivation may be prevented or reduced by polymers.Methods The maximum surface tension(γmax) and minimum surface tension(γmin) of nonionic polymer dextran,polyethylene glycol(PEG),ionic polymer hyaluronan(HA),PS,plasma and their mixtures by captive bubble surfactometer were measured,respectively.Their respective stability index(S.I.) was calculated.Results The minimum of the different polymers,plasma and their mixtures were more than 10 mN-m and the S.I.were less than 0.8.The γmin and S.I.of PS(0.84 g·L-1) were(1.78±0.03) mN-m and 1.71±0.01,respectively.Different of polymers significantly enhanced the ability of PS to lower the γmin and increased S.I.in presence of plasma.The γmin and S.I.of PS mixed with 1%,2%,3% plasma were(21.96±0.15) mN-m,(22.31±0.34) mN-m and(28.02±1.36) mN-m;0.14±0.03,0.12±0.01 and 0.36±0.03,respectively.When mixed with 5% PEG,5% Dextran or 0.25% HA,the γmin decreased to(1.60±0.04) mN-m,(1.35±0.06) mN-m,(18.66±0.73) mN-m;(1.13±0.01) mN-m,(1.28±0.01) mN-m,(16.68±0.31) mN-m and(1.16±0.01) mN-m,(1.22±0.01) mN-m,(1.23±0.01) mN-m,respectively,and the S.I.were 1.76±0.01,1.77±0.01,0.31±0.03;1.82±0.01,1.80±0.00,0.46±0.03 and 1.82±0.01,1.81±0.00,1.81±0.01,respectively.The similar effect were seen when different concentrations of polymers with PS and plasma.The γmin of PEG(0%,2.5%,5.0%,10.0%)+PS+plasma(2%) group were(22.32±0.34) mN-m,(1.09±0.01) mN-m,(1.35±0.06) mN-m,(0.96±0.02) mN-m,respectively;the γmin of Dextran(0%,2.5%,5.0%,10.0%)+PS+plasma group were(22.32±0.34) mN-m,(2.03±0.04) mN-m,(1.28±0.01) mN-m,(1.10±0.09) mN-m,respectively;the γmin of HA(0%,0.125%,0.250%,0.500%)+PS+plasma group were(22.32±0.34) mN-m,(9.60±0.20) mN-m,(1.22±0.01) mN-m,(0.92±0.01) mN-m,respectively.Conclusions The PS made in China has good ability to reduce the surface tension.Nonionic and ionic polymers can reverse inactivation of surfactant induced by plasma in vitro.HA may be more effective than PEG and Dextran when mixed with PS.
出处 《实用儿科临床杂志》 CAS CSCD 北大核心 2011年第14期1115-1118,共4页 Journal of Applied Clinical Pediatrics
基金 北京自然科学基金(7042018)
关键词 高分子聚合物 肺表面活性物质 血浆 最小表面张力 稳定系数 polymer pulmonary surfactant plasma minimum surface tension stability index
  • 相关文献

参考文献17

  • 1Howell EA, Holzman I, Kleinman LC,et al. Surfactant use for premature infants with respiratory distress syndrome in three new york city hospi- tals: Discordance of practice from a community clinician consensus standard[J]. J Perinatol,2010,30(9) :590 -595.
  • 2Van Kaam AH, de Jaegere AP, Borensztajn D, et al. Surfaetant replace- ment therapy in preterm infants : A European survey [ J ]. Neonatology, 2011,100(1 ) :71 -77.
  • 3甘小庄,宋国维.欧洲新生儿呼吸窘迫综合征治疗共识指南介绍[J].实用儿科临床杂志,2008,23(14):1136-1140. 被引量:27
  • 4邓渊,董声焕,张广安,马金贵.可控闭泡式表面张力测定仪的研制[J].中国医疗器械杂志,1994,18(2):87-89. 被引量:6
  • 5Lu KW, Perez -Gil J, Taeusch HW. Kinematic viscosity of therapeutic pulmonary surfactants with added polymers [J]. Biochim Biophys Acta, 2009,1788 (3) :632 - 637.
  • 6孙丽萍,甘小庄,董声焕,宋国维.高分子聚合物逆转血浆所致肺表面活性物质失活[J].国际儿科学杂志,2008,35(4):298-301. 被引量:1
  • 7甘小庄,宋国维,黄伟雄,孙丽萍,马广松,李惠.肺表面活性物质功能不良的机制探讨[J].中国危重病急救医学,1996,8(3):136-138. 被引量:3
  • 8Zasadzinski JA, Stenger PC, Shieh f,et al. Overcoming rapid inactivation of lung surfactant:Analogies between competitive adsorption and colloid stability [J]. Biochim Biophys Acta,2010,1798 (4) : 801 - 828.
  • 9Iwanicki JL, Lu KW, Taeusch HW. Reductions of phospholipase A (2) inhibition of pulmonary surfactant with hyaluronan [ J ]. Exp Lung Res, 2010,36(3) :167 - 174.
  • 10Lopez- Rodriguez E,Echaide M,Cruz A,et al. Meconium impairs pul- monary surfactant by a combined action of cholesterol and bile acids [J]. Biophys J, 2011,100 ( 3 ) : 646 - 655.

二级参考文献14

  • 1邓渊,董声焕,张广安,马金贵.可控闭泡式表面张力测定仪的研制[J].中国医疗器械杂志,1994,18(2):87-89. 被引量:6
  • 2Lewis JF, Veldhuizen R. The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol, 2003,65 : 613-642.
  • 3Schurch S,Bachofen H,Goerke J,et al.A captive bubble method reproduces the in situ behavior of lung surfactant monolayers. Appl Physiol, 1989,67(6) : 2389-2396.
  • 4Schurch S, Bachofen H, Goerke J, et al. Surface properties of rat pulmonary surfactant studied with the captive bubble mothed: adsorption, hysteresis, stability. Biochim Biophys Acta, 1992,1103( 1 ) : 127-136.
  • 5Taeusch HW. Treatment of acute (adult) respiratory distress syndrome: the holy grail of surfactant therapy. Biol Neonate,.2000,77 Suppl 1:2-8.
  • 6Frerking I, Gtinther A, Seeger W, et al. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med, 2001,27( 11 ) : 1699-1717.
  • 7Taeusch HW,Lu KW,Goerke J,et al.Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med, 1999,159 (5 Pt 1):1391-1395.
  • 8Kobayashi T, Ohta K, Tashiro K, et al. Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract . Appl Physiol, 1999, 86 (6) : 1778-1784.
  • 9Lu KW, Goerke J, Clements JA, et al. Hyaluronan decreases surfactant inactivation in vitro. Pediatr Res, 2005,57(2):237-241.
  • 10Sun B,Curstedt T,Lindgren G,et al .Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A. Eur Respir J, 1997,10(9) : 1967-1974.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部